Oncodesign Precision Medicine (XPAR:ALOPM) Goodwill: €0.00 Mil (As of Dec. 2025)


XPAR:ALOPM Oncodesign Precision Medicine SA XPAR:ALOPM
33 GF Score
Price €0.34
GF Value €0.29
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine Goodwill?

Oncodesign Precision Medicine XPAR:ALOPM +3.94% 33 Goodwill is €0.00 Mil as of Dec. 2025. GuruFocus rates XPAR:ALOPM with a GF Score™ of 33/100 and a GF Value™ of €0.29 (Modestly Overvalued). The stock has 1 warning sign investors should review.

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Oncodesign Precision Medicine's goodwill for the quarter that ended in Dec. 2025 was €0.00 Mil.


Oncodesign Precision Medicine  (XPAR:ALOPM) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Oncodesign Precision Medicine's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Goodwill-to-Asset (A: Dec. 2025 )=Goodwill/Total Assets
=0/14.988
=0.00

Oncodesign Precision Medicine's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

Goodwill-to-Asset (Q: Dec. 2025 )=Goodwill/Total Assets
=0/14.988
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Oncodesign Precision Medicine Goodwill Related Terms


Oncodesign Precision Medicine Goodwill Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Goodwill Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Goodwill
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:ALOPM
33GF Score
Oncodesign Precision Medicine SA XPAR:ALOPM
Goodwill is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncodesign Precision Medicine Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.

Frequently Asked Questions Learn more about Goodwill →
What does a Goodwill of €0.00 Mil mean?
Oncodesign Precision Medicine (XPAR:ALOPM) has a Goodwill of €0.00 Mil as of Dec. 2025. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Oncodesign Precision Medicine and its competitors.
Is Oncodesign Precision Medicine's Goodwill too high?
Oncodesign Precision Medicine's current Goodwill is €0.00 Mil. Overall, Oncodesign Precision Medicine has a GF Score™ of 33/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Goodwill compare to VRTX and REGN?
Oncodesign Precision Medicine's Goodwill of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill for a Biotechnology company?
A good Goodwill depends on the Biotechnology industry context. However, Goodwill should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill mean?
A high Goodwill can signal that a stock is expensive relative to its fundamentals. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current Goodwill is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (XPAR:ALOPM) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.29, compared to a current price of €0.34 — trading 18.3% above its estimated fair value. The current Goodwill is €0.00 Mil. Oncodesign Precision Medicine's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill calculated?
Goodwill is calculated from a company's financial statements. For Oncodesign Precision Medicine (XPAR:ALOPM), the current Goodwill is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (XPAR:ALOPM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.34 is trading 18.3% above its estimated GF Value™ of €0.29. GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.

Key valuation signals for XPAR:ALOPM:

  • Goodwill: €0.00 Mil
  • GF Value™: €0.29 vs. price of €0.34 (18.3% above fair value)
  • GF Score™: 33/100 with 1 warning sign

No single metric tells the full story. See the XPAR:ALOPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncodesign Precision Medicine Business Description

Other Exchanges ZR8:Germany
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
33GF Score

Get the complete analysis for XPAR:ALOPM

Goodwill is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price
€0.29
GF Value